BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 38138293)

  • 1. Exploring the Multifaceted Potential of Sildenafil in Medicine.
    Pușcașu C; Zanfirescu A; Negreș S; Șeremet OC
    Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gender-specific immunological effects of the phosphodiesterase 5 inhibitor sildenafil in healthy mice.
    Karakhanova S; Yang Y; Link J; Soltek S; von Ahn K; Umansky V; Werner J; Bazhin AV
    Mol Immunol; 2013 Dec; 56(4):649-59. PubMed ID: 23911424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nebivolol potentiates the efficacy of PDE5 inhibitors to relax corpus cavernosum and penile arteries from diabetic patients by enhancing the NO/cGMP pathway.
    Martínez-Salamanca JI; La Fuente JM; Cardoso J; Fernández A; Cuevas P; Wright HM; Angulo J
    J Sex Med; 2014 May; 11(5):1182-92. PubMed ID: 24877179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sildenafil inhibits hypoxia-induced transient receptor potential canonical protein expression in pulmonary arterial smooth muscle via cGMP-PKG-PPARγ axis.
    Wang J; Yang K; Xu L; Zhang Y; Lai N; Jiang H; Zhang Y; Zhong N; Ran P; Lu W
    Am J Respir Cell Mol Biol; 2013 Aug; 49(2):231-40. PubMed ID: 23526219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct allostery induced in the cyclic GMP-binding, cyclic GMP-specific phosphodiesterase (PDE5) by cyclic GMP, sildenafil, and metal ions.
    Biswas KH; Visweswariah SS
    J Biol Chem; 2011 Mar; 286(10):8545-8554. PubMed ID: 21193396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ca2+ -activated K+ channel (KCa) stimulation improves relaxant capacity of PDE5 inhibitors in human penile arteries and recovers the reduced efficacy of PDE5 inhibition in diabetic erectile dysfunction.
    González-Corrochano R; La Fuente J; Cuevas P; Fernández A; Chen M; Sáenz de Tejada I; Angulo J
    Br J Pharmacol; 2013 May; 169(2):449-61. PubMed ID: 23441682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beyond Erectile Dysfunction: cGMP-Specific Phosphodiesterase 5 Inhibitors for Other Clinical Disorders.
    Samidurai A; Xi L; Das A; Kukreja RC
    Annu Rev Pharmacol Toxicol; 2023 Jan; 63():585-615. PubMed ID: 36206989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repurposing of the PDE5 Inhibitor Sildenafil for the Treatment of Persistent Pulmonary Hypertension in Neonates.
    Poitras EL; Gust SL; Kerr PM; Plane F
    Curr Med Chem; 2021; 28(12):2418-2437. PubMed ID: 32964819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sildenafil reduces respiratory muscle weakness and fibrosis in the mdx mouse model of Duchenne muscular dystrophy.
    Percival JM; Whitehead NP; Adams ME; Adamo CM; Beavo JA; Froehner SC
    J Pathol; 2012 Sep; 228(1):77-87. PubMed ID: 22653783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphodiesterase 5 (PDE5) inhibition, ANP and NO rapidly reduce epididymal duct contractions, but long-term PDE5 inhibition in vivo does not.
    Mietens A; Tasch S; Feuerstacke C; Eichner G; Volkmann J; Schermuly RT; Grimminger F; Müller D; Middendorff R
    Mol Cell Endocrinol; 2012 Feb; 349(2):145-53. PubMed ID: 21996373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction.
    Corbin JD; Francis SH; Webb DJ
    Urology; 2002 Sep; 60(2 Suppl 2):4-11. PubMed ID: 12414329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds.
    Turko IV; Ballard SA; Francis SH; Corbin JD
    Mol Pharmacol; 1999 Jul; 56(1):124-30. PubMed ID: 10385692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transient rise of serum testosterone level after single sildenafil treatment of adult male rats.
    Janjic MM; Stojkov NJ; Bjelic MM; Mihajlovic AI; Andric SA; Kostic TS
    J Sex Med; 2012 Oct; 9(10):2534-43. PubMed ID: 22429315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PDE5 inhibitors - pharmacology and clinical applications 20 years after sildenafil discovery.
    Andersson KE
    Br J Pharmacol; 2018 Jul; 175(13):2554-2565. PubMed ID: 29667180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphodiesterase 5 Associates With β2 Adrenergic Receptor to Modulate Cardiac Function in Type 2 Diabetic Hearts.
    West TM; Wang Q; Deng B; Zhang Y; Barbagallo F; Reddy GR; Chen D; Phan KS; Xu B; Isidori A; Xiang YK
    J Am Heart Assoc; 2019 Aug; 8(15):e012273. PubMed ID: 31311394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro.
    Wallis RM; Corbin JD; Francis SH; Ellis P
    Am J Cardiol; 1999 Mar; 83(5A):3C-12C. PubMed ID: 10078537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antenatal sildenafil treatment attenuates pulmonary hypertension in experimental congenital diaphragmatic hernia.
    Luong C; Rey-Perra J; Vadivel A; Gilmour G; Sauve Y; Koonen D; Walker D; Todd KG; Gressens P; Kassiri Z; Nadeem K; Morgan B; Eaton F; Dyck JR; Archer SL; Thébaud B
    Circulation; 2011 May; 123(19):2120-31. PubMed ID: 21537000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic investigation of sildenafil using positron emission tomography and determination of its effect on cerebrospinal fluid cGMP levels.
    Gómez-Vallejo V; Ugarte A; García-Barroso C; Cuadrado-Tejedor M; Szczupak B; Dopeso-Reyes IG; Lanciego JL; García-Osta A; Llop J; Oyarzabal J; Franco R
    J Neurochem; 2016 Jan; 136(2):403-15. PubMed ID: 26641206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resveratrol and sildenafil synergistically improve diabetes-associated erectile dysfunction in streptozotocin-induced diabetic rats.
    Bai Y; An R
    Life Sci; 2015 Aug; 135():43-8. PubMed ID: 26006044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphodiesterase 5 inhibition ameliorates angiotensin II-dependent hypertension and renal vascular dysfunction.
    Thieme M; Sivritas SH; Mergia E; Potthoff SA; Yang G; Hering L; Grave K; Hoch H; Rump LC; Stegbauer J
    Am J Physiol Renal Physiol; 2017 Mar; 312(3):F474-F481. PubMed ID: 28052870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.